<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975104</url>
  </required_header>
  <id_info>
    <org_study_id>20080733</org_study_id>
    <nct_id>NCT00975104</nct_id>
  </id_info>
  <brief_title>AMG 745 in Subjects With Age-associated Muscle Loss</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and
      Efficacy of AMG 745 in Age-associated Muscle Loss
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Amgen has chosen at this time not to continue with AMG 745 study 20080733
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of AMG 745 weekly IV doses of 0.3 mg/kg, 1.0 mg/kg, or 3.0 mg/kg, compared with weekly IV placebo on thigh muscle CSA in subjects ≥ 65 yrs old with limited exercise tolerance and functional limitations</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment with AMG 745 on muscle strength (hand grip strength) and function (gait speed, 10-step stair climb power, chair stand and 6 minute walk distance) and to evaluate the PK of AMG 745 following multiple IV administrations</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Age-associated Muscle Loss</condition>
  <arm_group>
    <arm_group_label>AMG 745 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg AMG 745</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 745 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg, AMG 745</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 745 3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg, AMG 745</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 745 0.3 mg/kg</intervention_name>
    <description>AMG 745 0.3 mg/kg IV QW</description>
    <arm_group_label>AMG 745 0.3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 745 1.0 mg/kg</intervention_name>
    <description>AMG 745 1.0 mg/kg IV QW</description>
    <arm_group_label>AMG 745 1.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 745 3.0 mg/kg</intervention_name>
    <description>AMG 745 3.0 mg/kg IV QW</description>
    <arm_group_label>AMG 745 3.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV QW</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Limited exercise tolerance and Rapid Assessment of Physical Activity (RAPA) score ≤ 3

          -  Hand grip (dominant hand): men ≤ 30.3 kg, women ≤ 19.3 kg

          -  Walk speed ≤ 0.8 m/s (based on a 4 meter walk)

        Exclusion Criteria:

          -  Subject weight &gt; 137 kg (300 lbs), or Body Mass Index (BMI) &gt; 32 kg/m2

          -  Primary muscle disease or myopathy

          -  Recent immobilization, or major trauma to the legs within 6 months

          -  Knee or hip replacement within 12 months or lower extremity amputation

          -  Significant laboratory abnormalities

          -  Significant comorbidities or medical history

          -  Weight loss (intentional or unintentional) of &gt; 5 kg in 12 weeks

          -  Unable to complete an MRI scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>July 22, 2010</last_update_submitted>
  <last_update_submitted_qc>July 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Frailty</keyword>
  <keyword>Sedentary</keyword>
  <keyword>Immobilization</keyword>
  <keyword>Atrophy</keyword>
  <keyword>Muscle Wasting</keyword>
  <keyword>Physical Activity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

